Aesica Pharmaceuticals S.r.l. Meets New Serialization Requirements with a QAD ERP Upgrade
QAD Enterprise Applications Enterprise Edition facilitated speedy compliance for the Chinese market
SANTA BARBARA, Calif. — July 8, 2014 — QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services, announced today that Aesica Pharmaceuticals S.r.l., the Italian division of Aesica Pharmaceuticals Limited, has upgraded to QAD Enterprise Applications Enterprise Edition (QAD EE). The upgrade helped Aesica meet the deadline for a new serialization regulation for the Chinese market. A recently published case study shares the complete details of the implementation and its benefits.
Aesica is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company, operating in a highly regulated industry, had to meet product serialization and tracking regulations to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process and minimizing financial loss.
Aesica Pharmaceuticals was faced with an unexpected challenge when the compliance deadline for a new Chinese serialization regulation was accelerated from twelve-months to three-months. To meet the accelerated deadline, Aesica chose to upgrade to QAD EE, which helped Aesica meet the new serialization regulations.
“QAD has been a great partner to help Aesica meet the unexpectedly accelerated deadline from China,” said Maurizio Beninati, IT Manager Italy, Aesica Pharmaceuticals S.r.l. “We couldn’t have conquered this challenge without their help and expertise.”
With the successful implementation, Aesica can now:
- Identify each individual packaging unit down to the smallest sellable unit.
- Aggregate individual unit serial numbers as packages are bundled, boxed and placed on shipping pallets.
- Seamlessly track and trace each single pack of medication.
- Report serial numbers to the required government agencies once products have been produced and imported.
Aesica Pharmaceuticals S.r.l. supplies contract development and contract manufacturing services for finished dose and active pharmaceutical ingredients to the world’s leading pharmaceutical companies and emerging biotechnology organizations. With headquarters in the United Kingdom, it is one of the country’s fastest growing companies. Aesica currently employs approximately 1,300 people at its headquarters in Newcastle upon Tyne and at manufacturing sites in Cramlington, Nottingham and Queenborough in the U.K., as well as Monheim and Zwickau in Germany and Pianezza, Italy. Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011. For additional information go to www.aesica-pharma.co.uk .
For media enquiries, please contact Alex Maw, Marketing Director on +44(0)191 2181963 or email firstname.lastname@example.org
About QAD – The Effective Enterprise
QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB) is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 30 years, QAD has provided global manufacturing companies with QAD Enterprise Applications, an enterprise resource planning (ERP) system that supports operational requirements, including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD Enterprise Applications is offered in flexible deployment models as on-premise software, in the cloud with QAD Cloud ERP or in a blended environment. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.
For more information about QAD, call +1 805-566-6000 or visit www.qad.com.
“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
For additional information, contact:
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, “would”, “might”, “plan” and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for its fiscal year ended January 31, 2014, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.